

amended claims marked up to show the changes relative to the previous version thereof is attached hereto as **Exhibit A**. In addition, please add new claims 41-48 as follows.

--24. (Amended) A method for promoting wound healing in a

Applicants : Thomas M. Jessell et al.
Serial No. : Not Yet Known
Filed : November 2, 2001
Page 3

subject comprising administering to the subject a composition, which composition comprises an amount of the isolated dorsalin-1 polypeptide of claim 17 or 19 effective to promote wound healing, so as to promote wound healing in the subject.--

--25. (Amended) A method for treating a neural tumor in a subject comprising administering to the subject a composition, which composition comprises an amount of the isolated dorsalin-1 polypeptide of claim 17 or 19 effective to inhibit tumor cell growth, so as to thereby treat the neural tumor in the subject.--

--26. (Amended) The method of claim 25, wherein the neural tumor is a neurofibroma.--

--27. (Amended) The method of claim 25, wherein the neural tumor is a Schwann cell tumor.--

--36. (Amended) An antibody capable of specifically binding to the isolated dorsalin-1 polypeptide of claim 17 or 19.

--37. (Amended) The antibody of claim 36, wherein the antibody is a monoclonal antibody.

--38. (Amended) The antibody of claim 36, wherein the antibody is capable of inhibiting the biological activity of dorsalin-1 polypeptide.--

--39. (Amended) A method for inhibiting the activity of dorsalin-1 polypeptide in a subject comprising administering to the subject an amount of the antibody of claim 38 effective to inhibit the the activity of dorsalin-1, so as to thereby inhibit the the acitivity

Applicants : Thomas M. Jessell et al.
Serial No. : Not Yet Known
Filed : November 2, 2001
Page 4

of dorsalin-1 polypeptide.--

a4
cont
--40. (Amended) A pharmaceutical composition for inhibiting the activity of dorsalin-1 polypeptide comprising an amount of the antibody of claim 38 effective to inhibit the activity of dorsalin-1 polypeptide and a pharmaceutically acceptable carrier.--

10002278-110201
--41. (New) A pharmaceutical composition comprising the isolated dorsalin-1 polypeptide of claim 17 or 19 and a pharmaceutically acceptable carrier.--

--42. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to stimulate neural crest cell differentiation.--

--43. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to regenerate a nerve cell in a subject.--

a5
--44. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote bone growth in a subject.--

--45. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote wound healing in a subject.--

--46. (New) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to